论文部分内容阅读
目的观察射波刀联合热疗及替吉奥治疗原发性肝癌复发转移的临床疗效及安全性。方法选择2013-01/2015-01月在作者医院治疗的84例原发性肝癌治疗结束后复发转移患者,按不同治疗方案分为对照组和观察组。对照组43例行射波刀联合热疗,观察组41例行射波刀联合热疗及替吉奥治疗。结果治疗后3个月总有效率为79.76%,观察组的有效率,1年、2年局部控制率分别为87.80%、60.00%、35.00%,均高于对照组的72.09%、46.34%、24.39%,但组间比较差异无统计学意义(P>0.05)。对照组的1年、3年生存率和中位生存期分别为46.34%、7.32%、10.5个月,观察组的1年、3年生存率和中位生存期分别为65.00%、17.50%、13.5个月,组间比较差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论射波刀联合热疗及替吉奥是治疗原发性肝癌复发转移的一种既安全又有效的方法。
Objective To observe the clinical efficacy and safety of radiosurgery combined with hyperthermia and treatment of primary hepatocellular carcinoma recurrence and metastasis. Methods Eighty - four patients with primary hepatocellular carcinoma (HCC) who relapsed and metastasized at the author hospital from January 2013 to January 2015 were enrolled and divided into control group and observation group according to different treatment plans. In the control group, 43 cases were treated with radiosurgery combined with hyperthermia. The observation group consisted of 41 cases treated with radiosurgery combined with hyperthermia and treatment of tegmentalgia. Results The total effective rate was 79.76% at 3 months after treatment. The effective rate in the observation group was 87.80%, 60.00% and 35.00% at 1 year and 2 years respectively, which were all higher than those in the control group (72.09% and 46.34% 24.39%, but there was no significant difference between the two groups (P> 0.05). The 1-year, 3-year and median survival rates of the control group were 46.34%, 7.32% and 10.5 months, respectively. The 1-year, 3-year survival rates and median survival rates of the observation group were 65.00% and 17.50% 13.5 months, the difference between the groups was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Radiotherapy combined with hyperthermia and tigao is a safe and effective method for the treatment of recurrence and metastasis of primary liver cancer.